Which has preferable earnings & valuation, RGNX or PHVS?

REGENXBIO has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 3.30 -$193.88M -$3.79 N/A Pharvaris N/A N/A -$198.79M -$3.05 N/A

Is RGNX or PHVS more profitable?

Pharvaris has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Pharvaris' return on equity of -61.40% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -112.58% -220.07% -46.04% Pharvaris N/A -61.40% -56.00%

Does the media favor RGNX or PHVS?

In the previous week, Pharvaris had 37 more articles in the media than REGENXBIO. MarketBeat recorded 40 mentions for Pharvaris and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.73 beat Pharvaris' score of 0.55 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 12 Very Positive mention(s) 8 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RGNX or PVLA?

In the previous week, Palvella Therapeutics had 8 more articles in the media than REGENXBIO. MarketBeat recorded 11 mentions for Palvella Therapeutics and 3 mentions for REGENXBIO. Palvella Therapeutics' average media sentiment score of 1.21 beat REGENXBIO's score of 0.73 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RGNX or MESO?

Mesoblast has lower revenue, but higher earnings than REGENXBIO. Mesoblast is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 3.30 -$193.88M -$3.79 N/A Mesoblast $120.25M 16.72 -$57.50M -$0.28 N/A

Is RGNX or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Mesoblast's return on equity of 0.00% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -112.58% -220.07% -46.04% Mesoblast N/A N/A N/A

Is RGNX or KOD more profitable?

Kodiak Sciences has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. REGENXBIO's return on equity of -220.07% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -112.58% -220.07% -46.04% Kodiak Sciences N/A -273.23% -85.48%

Does the media favor RGNX or KOD?

In the previous week, Kodiak Sciences had 1 more articles in the media than REGENXBIO. MarketBeat recorded 4 mentions for Kodiak Sciences and 3 mentions for REGENXBIO. Kodiak Sciences' average media sentiment score of 1.44 beat REGENXBIO's score of 0.73 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ADMA or RGNX?

ADMA Biologics has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $510.17M 4.05 $146.93M $0.70 13.19 REGENXBIO $170.44M 3.30 -$193.88M -$3.79 N/A

Is ADMA or RGNX more profitable?

ADMA Biologics has a net margin of 32.98% compared to REGENXBIO's net margin of -112.58%. ADMA Biologics' return on equity of 40.17% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.98% 40.17% 26.97% REGENXBIO -112.58% -220.07% -46.04%

Does the media refer more to ADMA or RGNX?

In the previous week, ADMA Biologics had 2 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for ADMA Biologics and 3 mentions for REGENXBIO. ADMA Biologics' average media sentiment score of 1.09 beat REGENXBIO's score of 0.73 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

REGENXBIO (RGNX) Competitors

$8.53 -0.03 (-0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$8.59 +0.06 (+0.70%)

As of 07:30 PM Eastern

Compare

RGNX vs. PHVS, PVLA, MESO, KOD, and ADMA

Should you buy REGENXBIO stock or one of its competitors? REGENXBIO's main competitors and comparable companies include Pharvaris (PHVS), Palvella Therapeutics (PVLA), Mesoblast (MESO), Kodiak Sciences (KOD), and ADMA Biologics (ADMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does REGENXBIO compare to Pharvaris?

REGENXBIO (NASDAQ:RGNX) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

88.1% of REGENXBIO shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

REGENXBIO has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.30	-$193.88M	-$3.79	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

In the previous week, Pharvaris had 37 more articles in the media than REGENXBIO. MarketBeat recorded 40 mentions for Pharvaris and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.73 beat Pharvaris' score of 0.55 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	12 Very Positive mention(s)	8 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

REGENXBIO has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, meaning that its share price is 333% less volatile than the broader market.

Pharvaris has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Pharvaris' return on equity of -61.40% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Pharvaris	N/A	-61.40%	-56.00%

REGENXBIO currently has a consensus price target of $23.27, indicating a potential upside of 172.83%. Pharvaris has a consensus price target of $59.50, indicating a potential upside of 56.50%. Given REGENXBIO's higher possible upside, equities research analysts clearly believe REGENXBIO is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

REGENXBIO beats Pharvaris on 8 of the 14 factors compared between the two stocks.

How does REGENXBIO compare to Palvella Therapeutics?

REGENXBIO (NASDAQ:RGNX) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

REGENXBIO currently has a consensus price target of $23.27, indicating a potential upside of 172.83%. Palvella Therapeutics has a consensus price target of $209.14, indicating a potential upside of 39.31%. Given REGENXBIO's higher possible upside, analysts clearly believe REGENXBIO is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

REGENXBIO has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Palvella Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Palvella Therapeutics' return on equity of -47.84% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Palvella Therapeutics	N/A	-47.84%	-38.33%

In the previous week, Palvella Therapeutics had 8 more articles in the media than REGENXBIO. MarketBeat recorded 11 mentions for Palvella Therapeutics and 3 mentions for REGENXBIO. Palvella Therapeutics' average media sentiment score of 1.21 beat REGENXBIO's score of 0.73 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics has lower revenue, but higher earnings than REGENXBIO. Palvella Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.30	-$193.88M	-$3.79	N/A
Palvella Therapeutics	$42.81M	50.53	-$41.72M	-$4.83	N/A

Summary

Palvella Therapeutics beats REGENXBIO on 11 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Mesoblast?

REGENXBIO (NASDAQ:RGNX) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Mesoblast has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Mesoblast's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Mesoblast	N/A	N/A	N/A

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

REGENXBIO has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

Mesoblast has lower revenue, but higher earnings than REGENXBIO. Mesoblast is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.30	-$193.88M	-$3.79	N/A
Mesoblast	$120.25M	16.72	-$57.50M	-$0.28	N/A

REGENXBIO presently has a consensus price target of $23.27, indicating a potential upside of 172.83%. Mesoblast has a consensus price target of $39.00, indicating a potential upside of 151.94%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts plainly believe REGENXBIO is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, REGENXBIO had 2 more articles in the media than Mesoblast. MarketBeat recorded 3 mentions for REGENXBIO and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.77 beat REGENXBIO's score of 0.73 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Overall Sentiment
REGENXBIO	Positive
Mesoblast	Positive

Summary

Mesoblast beats REGENXBIO on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Kodiak Sciences?

REGENXBIO (NASDAQ:RGNX) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Kodiak Sciences had 1 more articles in the media than REGENXBIO. MarketBeat recorded 4 mentions for Kodiak Sciences and 3 mentions for REGENXBIO. Kodiak Sciences' average media sentiment score of 1.44 beat REGENXBIO's score of 0.73 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. REGENXBIO's return on equity of -220.07% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Kodiak Sciences	N/A	-273.23%	-85.48%

REGENXBIO has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market.

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

REGENXBIO has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.30	-$193.88M	-$3.79	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

REGENXBIO currently has a consensus target price of $23.27, indicating a potential upside of 172.83%. Kodiak Sciences has a consensus target price of $48.14, indicating a potential upside of 46.38%. Given REGENXBIO's higher possible upside, research analysts plainly believe REGENXBIO is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

REGENXBIO beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and REGENXBIO (NASDAQ:RGNX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

ADMA Biologics currently has a consensus target price of $18.67, indicating a potential upside of 102.24%. REGENXBIO has a consensus target price of $23.27, indicating a potential upside of 172.83%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts plainly believe REGENXBIO is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

In the previous week, ADMA Biologics had 2 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for ADMA Biologics and 3 mentions for REGENXBIO. ADMA Biologics' average media sentiment score of 1.09 beat REGENXBIO's score of 0.73 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.05	$146.93M	$0.70	13.19
REGENXBIO	$170.44M	3.30	-$193.88M	-$3.79	N/A

ADMA Biologics has a net margin of 32.98% compared to REGENXBIO's net margin of -112.58%. ADMA Biologics' return on equity of 40.17% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
REGENXBIO	-112.58%	-220.07%	-46.04%

ADMA Biologics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ADMA Biologics beats REGENXBIO on 10 of the 16 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGNX vs. The Competition

Export

Metric	REGENXBIO	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$565.07M	$3.86B	$7.17B	$12.72B
Dividend Yield	N/A	3.65%	2.57%	11.16%
P/E Ratio	-2.25	8.31	212.38	20.78
Price / Sales	3.30	1,371.42	631.75	90.65
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	4.20	15.13	10.33	6.20
Net Income	-$193.88M	-$22.82M	$3.49B	$358.27M
7 Day Performance	-4.59%	-4.31%	-3.29%	-2.35%
1 Month Performance	-19.91%	0.39%	-0.26%	-2.61%
1 Year Performance	-10.12%	38.28%	17.32%	8.08%

REGENXBIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGNX REGENXBIO	3.7185 of 5 stars	$8.53 -0.4%	$23.27 +172.8%	-10.6%	$565.07M	$170.44M	N/A	370
PHVS Pharvaris	3.7303 of 5 stars	$35.25 flat	$51.08 +44.9%	+61.3%	$2.31B	N/A	N/A	30	Trending News Analyst Forecast Insider Trade
PVLA Palvella Therapeutics	2.5151 of 5 stars	$157.24 flat	$209.14 +33.0%	+151.8%	$2.27B	$42.81M	N/A	N/A	Positive News Gap Up
MESO Mesoblast	1.8332 of 5 stars	$17.32 flat	$39.00 +125.2%	-0.4%	$2.25B	$120.25M	N/A	80
KOD Kodiak Sciences	2.1053 of 5 stars	$35.36 flat	$48.14 +36.2%	+237.8%	$2.22B	N/A	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Competitors

RGNX vs. PHVS, PVLA, MESO, KOD, and ADMA

How does REGENXBIO compare to Pharvaris?

Summary

How does REGENXBIO compare to Palvella Therapeutics?

Summary

How does REGENXBIO compare to Mesoblast?

Summary

How does REGENXBIO compare to Kodiak Sciences?

Summary

How does REGENXBIO compare to ADMA Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Competitors

RGNX vs. PHVS, PVLA, MESO, KOD, and ADMA

How does REGENXBIO compare to Pharvaris?

Do institutionals and insiders have more ownership in RGNX or PHVS?

Which has preferable earnings & valuation, RGNX or PHVS?

Does the media favor RGNX or PHVS?

Which has more volatility and risk, RGNX or PHVS?

Is RGNX or PHVS more profitable?

Do analysts prefer RGNX or PHVS?

Summary

How does REGENXBIO compare to Palvella Therapeutics?

Do analysts prefer RGNX or PVLA?

Do insiders & institutionals have more ownership in RGNX or PVLA?

Which has more risk and volatility, RGNX or PVLA?

Is RGNX or PVLA more profitable?

Does the media favor RGNX or PVLA?

Which has better valuation and earnings, RGNX or PVLA?

Summary

How does REGENXBIO compare to Mesoblast?

Is RGNX or MESO more profitable?

Do insiders and institutionals believe in RGNX or MESO?

Which has more risk and volatility, RGNX or MESO?

Which has preferable earnings and valuation, RGNX or MESO?

Do analysts rate RGNX or MESO?

Does the media favor RGNX or MESO?

Summary

How does REGENXBIO compare to Kodiak Sciences?

Does the media favor RGNX or KOD?

Is RGNX or KOD more profitable?

Which has more volatility & risk, RGNX or KOD?

Do institutionals and insiders believe in RGNX or KOD?

Which has higher earnings & valuation, RGNX or KOD?

Do analysts rate RGNX or KOD?

Summary

How does REGENXBIO compare to ADMA Biologics?

Do analysts prefer ADMA or RGNX?

Does the media refer more to ADMA or RGNX?

Which has better valuation & earnings, ADMA or RGNX?

Is ADMA or RGNX more profitable?

Which has more risk and volatility, ADMA or RGNX?

Do insiders & institutionals believe in ADMA or RGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools